Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-JNJ26489112 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 14C-JNJ26489112 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 14C-JNJ26489112 | DRUG | Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1. |
Inclusion Criteria: * Signed an informed consent document indicating they understand the purpose of and procedures required for the study, are willing to participate in the study, and are willing to adhere to the prohibitions and restrictions specified in the protocol * Had consistent bowel movemen...
14C-JNJ26489112 is an investigational small molecule being studied in healthy participants. It is a radiolabeled compound used in a Phase 1 clinical trial to evaluate its absorption, metabolism, and excretion in the body. The study is not intended to treat a disease but to understand how the drug behaves in healthy male volunteers.
14C-JNJ26489112 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical research on this investigational small molecule drug.
14C-JNJ26489112 is in Phase 1 clinical development. The single clinical trial for this drug has been completed. It is an investigational drug and has not been approved by regulatory authorities for any medical use.
14C-JNJ26489112 has one completed clinical trial registered as NCT01949610, titled "A Study to Evaluate Absorption, Metabolism, and Excretion of 14C-JNJ26489112 in Healthy Male Participants." This Phase 1 study enrolled 10 healthy male participants in Belgium and was not randomized or blinded.
14C-JNJ26489112 is a radiolabeled small molecule, meaning it contains a radioactive carbon isotope (14C) that allows researchers to track the drug's absorption, metabolism, and excretion in the body. This helps scientists understand how the compound is processed after administration.